All In Biotech

Drug Trial Radar · NCT05762146

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Ischaemic STROKE (REPO-STROKE IIa)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

28

Planned (sponsor's estimate)

Start

Sep 5, 2022

Primary completion

Feb 29, 2024

Study completion Apr 30, 2024

Sponsor

Lead sponsor
Maastricht UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A combination therapy proposed to be evaluated in this trial, consisting of three already registered compounds with a validated disease mechanism and with known safety profiles, targets key proteins in the dysregulated signal network in stroke, and is expected to synergistically result in post-stroke blood-brain barrier stabilization and neuroprotection. The synergistic mode of action will allow for low doses and is expected to reduce possible side effects while maintaining maximal efficacy

Conditions

  • Ischemic Stroke, Acute

Interventions

  • RiociguatDrug

    Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.

  • PropylthiouracilDrug

    Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors

  • PerphenazineDrug

    Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SICH as per ECASS IIITime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Essen, Department of Neurology

    Essen, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.